152 related articles for article (PubMed ID: 11521253)
1. Manufacturing misdeeds cost Abbott record-breaking payment.
Lewis C
FDA Consum; 2000; 34(3):38-9. PubMed ID: 11521253
[No Abstract] [Full Text] [Related]
2. Abbott Laboratories Consent Decree and individual responsibility under the Federal Food, Drug, and Cosmetic Act.
Blumberg EM
Food Drug Law J; 2000; 55(1):145-9. PubMed ID: 12322721
[No Abstract] [Full Text] [Related]
3. Urokinase and the US Food and Drug Administration.
Ouriel K
J Vasc Surg; 1999 Nov; 30(5):957-8. PubMed ID: 10550197
[No Abstract] [Full Text] [Related]
4. Separate manufacturing standards needed for veterinary drugs: AVMA.
J Am Vet Med Assoc; 1996 Feb; 208(4):461. PubMed ID: 8603886
[No Abstract] [Full Text] [Related]
5. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories.
Jimenez FA
Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711
[No Abstract] [Full Text] [Related]
6. Quality control and good manufacturing practices: safety and efficacy of commercial herbals.
Awang DV
Food Drug Law J; 1997; 52(3):341-4. PubMed ID: 10343036
[No Abstract] [Full Text] [Related]
7. The impact of Abbott's consent decree on clinical laboratories.
Assarian GS
MLO Med Lab Obs; 2000 Sep; 32(9):56-8. PubMed ID: 11184639
[No Abstract] [Full Text] [Related]
8. FDA's role in drug product recalls.
Crawford SY
Am J Hosp Pharm; 1991 Dec; 48(12):2595-6. PubMed ID: 1814194
[No Abstract] [Full Text] [Related]
9. Food and Drug Administration inspection and licensing of manufacturing facilities.
Avallone HL; Beatrice MG; Sze TT
Bioprocess Technol; 1991; 13():315-40. PubMed ID: 1367137
[No Abstract] [Full Text] [Related]
10. Remarks at the Food and Drug Law Institute's 48th Annual Conference.
Niedelman SM
Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089
[No Abstract] [Full Text] [Related]
11. Lessons learned from good manufacturing practice noncompliance.
Peskoe MP
Food Drug Law J; 1995; 50(1):65-70. PubMed ID: 10342986
[No Abstract] [Full Text] [Related]
12. FDA regulations and guidelines.
Rothschild A
J Parenter Sci Technol; 1990; 44(1):26-9. PubMed ID: 2313489
[No Abstract] [Full Text] [Related]
13. A strike against preemption.
Nat Biotechnol; 2009 May; 27(5):397. PubMed ID: 19430422
[TBL] [Abstract][Full Text] [Related]
14. The parenteral drug industry: recent findings.
Fry EM
J Parenter Sci Technol; 1982; 36(2):55-8. PubMed ID: 7077464
[No Abstract] [Full Text] [Related]
15. Double standards in GMP deduplication row.
Hodgson J; Fox JL
Nat Biotechnol; 1996 Dec; 14(13):1647-8. PubMed ID: 9634839
[No Abstract] [Full Text] [Related]
16. Medical device and Laboratory Product Problem Reporting Program (PRP).
AANA J; 1979 Feb; 47(1):5. PubMed ID: 442931
[No Abstract] [Full Text] [Related]
17. The case of Abbokinase and the FDA: the events leading to the suspension of Abbokinase supplies in the United States.
Hartnell GG; Gates J
J Vasc Interv Radiol; 2000; 11(7):841-7. PubMed ID: 10928519
[No Abstract] [Full Text] [Related]
18. Botanical drugs: a future for herbal medicines.
Li W
J Contemp Health Law Policy; 2002; 19(1):117-49. PubMed ID: 12733224
[No Abstract] [Full Text] [Related]
19. Off-label promotion.
Somberg J
Am J Ther; 2006; 13(5):387. PubMed ID: 16988530
[No Abstract] [Full Text] [Related]
20. Pediatric Research Equity Act.
J Natl Cancer Inst; 2004 Dec; 96(24):1810. PubMed ID: 15601636
[No Abstract] [Full Text] [Related]
[Next] [New Search]
